MCID: RBL001
MIFTS: 50

Rubella malady

Rare diseases, Infectious diseases, Skin diseases, Fetal diseases, Neuronal diseases categories

Aliases & Classifications for Rubella

About this section

Summaries for Rubella

About this section
MedlinePlus:35 Rubella is an infection caused by a virus. it is usually mild with fever and a rash. about half of the people who get rubella do not have symptoms. if you do get them, symptoms may include a rash that starts on the face and spreads to the body mild fever aching joints, especially in young women swollen glands rubella is most dangerous for a pregnant woman's baby. it can cause miscarriage or birth defects. rubella spreads when an infected person coughs or sneezes. people without symptoms can still spread it. there is no treatment, but the measles-mumps-rubella (mmr) vaccine can prevent it. centers for disease control and prevention

MalaCards based summary: Rubella, also known as german measles, is related to spinal polio and viral meningitis, and has symptoms including rash on the face which spreads to the trunk, fever and lymphadenopathy. An important gene associated with Rubella is CD40LG (CD40 Ligand), and among its related pathways are Peginterferon alpha-2a/Peginterferon alpha-2b Pathway (Hepatocyte), Pharmacodynamics and Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell. Affiliated tissues include skin, skin and eye, and related mouse phenotypes are hematopoietic system and immune system.

Disease Ontology:10 A viral infectious disease that results in infection located in skin, has material basis in rubella virus, which is transmitted by droplet spread of oronasal secretions from the infected person through coughing and sneezing, and transmitted by congenital method. the infection has symptom rash on the face which spreads to the trunk and limbs, has symptom fever, has symptom lymphadenopathy, has symptom joint pains, has symptom headache, and has symptom conjunctivitis.

CDC:2 Rubella is a contagious disease caused by a virus. It is also called German measles or three-day measles. But don't confuse rubella with measles, which is sometimes called rubeola. The two diseases have similar features, including a red rash, but they are caused by different viruses...

Wikipedia:68 Rubella, also known as German measles or three-day measles, is an infection caused by the rubella virus.... more...

Related Diseases for Rubella

About this section

Graphical network of the top 20 diseases related to Rubella:



Diseases related to rubella

Symptoms for Rubella

About this section

Symptoms:

 10
  • rash on the face which spreads to the trunk
  • fever
  • lymphadenopathy
  • joint pains
  • headache
  • conjunctivitis

Drugs & Therapeutics for Rubella

About this section

Drugs for Rubella (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 14)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Aluminum hydroxideapprovedPhase 3, Phase 2169
Synonyms:
Al(OH)3
Aluminiumhydroxid
 
Aluminum Hydroxide
Aluminum hydroxide
Dermadrox
2AlbunexPhase 3, Phase 2145
3PENTAPhase 3, Phase 2106
4
LactitolPhase 3, Phase 2313585-86-43871
Synonyms:
4-O-b-D-Galactopyranosyl-D-glucitol, 9CI
E966
Emportal
 
Floralac
Importal
Oponaf
Portolac
5
AltretamineapprovedPhase 251645-05-62123
Synonyms:
2,4, 6-Tris(dimethylamino)-1,3,5-triazine
2,4,6-Tris(dimethylami
2,4,6-Tris(dimethylamino)-1,3,5-triazine
2,4,6-Tris(dimethylamino)-S-triazine
2,4,6-Tris(dimethylamino)-s-triazine
2-N,2-N,4-N,4-N,6-N,6-N-hexamethyl-1,3,5-triazine-2,4,6-triamine
549835_ALDRICH
645-05-6
A 8723
A0567/0026158
A8723_SIGMA
AB00052308
AC-12006
AC1L1CYX
AI3-50852
AKOS001729401
Altretamin
Altretamina
Altretamina [INN-Spanish]
Altretamine (USP/INN)
Altretamine Bellon Brand
Altretamine Chiesi Brand
Altretamine Wassermann Brand
Altretamine [USAN:INN:BAN]
Altretaminum
Altretaminum [INN-Latin]
Altrétamine
BPBio1_001004
BRD-K67043667-001-04-1
BRN 0195058
BSPBio_000912
Bellon Brand of Altretamine
C9H18N6
CAS-654-05-6
CCRIS 5492
CHEBI:24564
CHEMBL1455
CID2123
CPD000058181
ChemDiv2_005185
Chiesi Brand of Altretamine
D006585
D02841
DB00488
DivK1c_000772
EINECS 211-428-4
ENT 50852
EU-0100083
FT-0083576
HEXAMETHYLMELAMINE
HMM
HMS1383L15
HMS1570N14
HMS1922C05
HMS2090G17
HMS2092H16
HMS502G14
HSDB 7559
HTM
HXM
Hemel
Hexalen
Hexalen (TN)
Hexalen, Altretamine
 
Hexamethylmelamine
Hexastat
Hexinawas
I06-0604
IDI1_000772
IDI1_003900
InChI=1/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H
KB-913
KBio1_000772
KBio2_001788
KBio2_004356
KBio2_006924
KBio3_002042
KBioGR_001388
KBioSS_001788
LS-1549
Lopac-A-8723
Lopac0_000083
MGI Pharma Brand of Altretamine
MLS000069621
MLS001076123
MolPort-002-111-210
N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine
NC 195
NCGC00015100-01
NCGC00015100-02
NCGC00015100-03
NCGC00015100-06
NCGC00015100-11
NCGC00021216-03
NCGC00021216-04
NCGC00021216-05
NCGC00021216-06
NCGC00021216-07
NCI-C50259
NCI60_000871
NINDS_000772
NSC 13875
NSC-13875
NSC13875
N~2~,N~2~,N~4~,N~4~,N~6~,N~6~-Hexamethyl-1,3,5-triazine-2,4,6-triamine
Prestwick0_000946
Prestwick1_000946
Prestwick2_000946
Prestwick3_000946
Rhone Poulenc Rorer Brand of Altretamine
Rhone-Poulenc Rorer Brand of Altretamine
S1278_Selleck
SAM002564241
SMR000058181
SPBio_000754
SPBio_003071
SPECTRUM1503065
ST086739
STK749184
Spectrum2_000907
Spectrum3_000951
Spectrum4_001064
Spectrum5_001092
Spectrum_001308
UNII-Q8BIH59O7H
WLN: T6N CN ENJ BN1&1 DN1&1 FN1&1
Wassermann Brand of Altretamine
ZINC00000905
altretamine
no)-s-triazine
6Immunoglobulin MPhase 19
7Immunoglobulin GPhase 1167
8
Infliximabapproved327170277-31-3
Synonyms:
Ig gamma-1 chain C region
 
Inflectra
Remicade
Remsima
9
Methotrexateapproved13871959-05-2, 59-05-2126941
Synonyms:
4-amino-10-methylfolic acid
4-amino-N(10)-Methylpteroylglutamic acid
Abitrexate
Amethopterin
Amethopterine
Antifolan
Arbitrexate
Emtexate
Folex
HDMTX
L-Amethopterin
Ledertrexate
MTX
Metatrexan
Methopterin
Methotextrate
 
Methotrate
Methotrexat
Methotrexate
Methotrexate Sodium
Methotrexatum
Methylaminopterin
Methylaminopterinum
Metoject
Metotrexato
Mexate
Méthotrexate
N-Bismethylpteroylglutamic Acid
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Otrexup
Rasuvo
Rheumatrex
Rheumatrex Dose Pack
Trexall
10
Certolizumab pegolapproved109428863-50-7
Synonyms:
428863-50-7
CDP870
Certolizumab pegol
 
Certolizumab pegol (USAN/INN)
Certolizumab pegol (genetical recombination)
Certolizumab pegol (genetical recombination) (JAN)
Cimzia
D03441
11
Adalimumabapproved411331731-18-116219006
Synonyms:
331731-18-1
Adalimumab
Adalimumab (USAN/INN)
Adalimumab (genetical recombination)
 
Adalimumab (genetical recombination) (JAN)
D02597
Humira
Humira (TN)
Humira Pen
Ig gamma-1 chain C region
12
Azathioprineapproved145446-86-62265
Synonyms:
446-86-6
55774-33-9 (hydrochloride salt)
6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine
6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine
6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]
6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine
6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-7H-purine
6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine
6-(Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(Methyl-p-nitro-5-imidazolyl)thiopurine
6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine
6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine
6-[(1-Methyl-4-nitroimidazol-5-yl)- thio] purine
6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine
A 4638
A2593_SIAL
A4638_SIAL
A4638_SIGMA
AB00443544
AB00443544-03
AC-4230
AC1L1DAL
AC1Q3Z1F
AI-981/34845012
AI3-50290
Azamun
Azamun [Czech]
Azanin
Azasan
Azasan (TN)
Azasan, Imuran, Azamun, BW-57-322, NSC-39084, Azathioprine
Azathioprin
Azathioprine
Azathioprine (JP15/USP/INN)
Azathioprine Sodium
Azathioprine [USAN:INN:BAN:JAN]
Azathioprine sodium
Azathioprinum
Azathioprinum [INN-Latin]
Azathiopurine
Azatioprin
Azatioprina
Azatioprina [INN-Spanish]
Azothioprine
B. W. 57-322
BPBio1_000054
BRD-K32821942-001-05-6
BRD-K60324116-001-01-5
BSPBio_000048
BSPBio_001876
BW 57-322
BW 57322
BW-57-322
C06837
C9H7N7O2S
CAS-446-86-6
CBDivE_013132
CCRIS 62
CHEBI:2948
CHEMBL1542
CID2265
CPD000427366
Ccucol
ChemDiv1_002659
Cytostatics
D00238
DB00993
DivK1c_000586
EINECS 207-175-4
EU-0100027
FT-0083532
HMS1568C10
 
HMS1920E17
HMS2091K19
HMS501N08
HMS594I19
HSDB 7084
IDI1_000586
Immuran
Imuran
Imuran (TN)
Imuran (tn)
Imurek
Imurel
KBio1_000586
KBio2_000464
KBio2_002427
KBio2_003032
KBio2_004995
KBio2_005600
KBio2_007563
KBio3_001376
KBio3_002906
KBioGR_000646
KBioGR_002427
KBioSS_000464
KBioSS_002433
LS-123
Lopac-A-4638
Lopac0_000027
MLS001049307
Methylnitroimidazolylmercaptopurine
MolPort-000-745-914
MolPort-000-764-262
MolPort-003-665-485
Muran
NCGC00015060-01
NCGC00015060-02
NCGC00015060-04
NCGC00015060-12
NCGC00090836-01
NCGC00090836-02
NCGC00090836-03
NCGC00090836-04
NCGC00090836-05
NCGC00090836-06
NCGC00094593-01
NCGC00094593-02
NCGC00094593-03
NCI-C03474
NINDS_000586
NSC 39084
NSC-39084
NSC39084
Oprea1_375441
Oprea1_533384
Oprea1_633462
Prestwick0_000094
Prestwick1_000094
Prestwick2_000094
Prestwick3_000094
Prestwick_41
S1721_Selleck
SAM002589938
SDCCGMLS-0065415.P001
SMR000427366
SPBio_000255
SPBio_001987
SPECTRUM1500133
STK831906
STOCK1S-20293
STOCK1S-27186
Spectrum2_000068
Spectrum3_000308
Spectrum4_000243
Spectrum5_000848
Spectrum_000064
Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl)
UNII-MRK240IY2L
WLN: T56 BM DN FN HNJ IS- ET5N CNJ A1 DNW
ZINC04258316
[Methyl(nitroimidazolyl)mercaptopurine]
azathioprine
azatiopr in
cMAP_000046
136-Mercaptopurine181
14AcidophilusNutraceutical444

Interventional clinical trials:

(show top 50)    (show all 116)
idNameStatusNCT IDPhase
1Coadministration of Measles-rubella and Rotavirus VaccinesCompletedNCT01700621Phase 4
2Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox DiseasesCompletedNCT00126997Phase 4
3Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic ArthritisCompletedNCT00731965Phase 4
4Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined VaccineCompletedNCT00313950Phase 4
5Measles, Mumps, and Rubella (MMR) Immunity in College StudentsCompletedNCT00962819Phase 4
6Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.CompletedNCT00388440Phase 4
7Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067)CompletedNCT00312858Phase 4
8Safety Study of a Refrigerator-Stable Formulation of VARIVAX®CompletedNCT00432731Phase 4
9MMR and Varicella Vaccine in Premature InfantsCompletedNCT00156559Phase 4
10IPV Clinical Trial - The GambiaCompletedNCT01847872Phase 4
11Study of the Influence of Vaccination in HIV Viral Load and Immunologic Responses Against HIVCompletedNCT00329251Phase 4
12Immunogenicity of Co-administration of Measles and Japanese Encephalitis VaccinesRecruitingNCT02643433Phase 4
13Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMRRecruitingNCT02325310Phase 4
14Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose PresentationsRecruitingNCT01777529Phase 4
15Induction of Immunity Against Measles in Pediatric Liver Transplant RecipientsRecruitingNCT01770119Phase 4
16Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old ChildrenActive, not recruitingNCT02253407Phase 4
17The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR VaccineEnrolling by invitationNCT02153866Phase 4
18Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella VaccinesTerminatedNCT00138255Phase 4
19Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese ToddlersCompletedNCT01188343Phase 3
20Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox DiseasesCompletedNCT00127023Phase 3
21Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)CompletedNCT01536405Phase 3
22Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and OlderCompletedNCT02058563Phase 3
23Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136CompletedNCT00751348Phase 3
24Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox DiseasesCompletedNCT00127010Phase 3
25Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTMCompletedNCT00969436Phase 3
26Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of LifeCompletedNCT01681992Phase 3
27Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of AgeCompletedNCT02184572Phase 3
28Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of AgeCompletedNCT01621802Phase 3
29Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy ToddlersCompletedNCT00422292Phase 3
30Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)CompletedNCT00092430Phase 3
31ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)CompletedNCT00975507Phase 3
32Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix®) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M M R®II), in Children 12 to 15 Months of AgeCompletedNCT01702428Phase 3
33Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)CompletedNCT00985153Phase 3
34A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)CompletedNCT00985166Phase 3
35Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety StudyCompletedNCT00326183Phase 3
36Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in ChildrenCompletedNCT00197015Phase 3
37Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined VaccineCompletedNCT00406211Phase 3
38Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered ConcomitantlyCompletedNCT00432042Phase 3
39Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy ToddlersCompletedNCT00483574Phase 3
40ProQuad® rHA SafetyCompletedNCT00560755Phase 3
41Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and ChickenpoxCompletedNCT00226499Phase 3
42Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy ChildrenCompletedNCT00192491Phase 3
43Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric VaccinesCompletedNCT00984295Phase 3
44Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy ChildrenCompletedNCT01506193Phase 3
45Comparative Study of Immunogenicity and Safety of a 2-Dose Regimen of ProQuad® Manufactured With rHACompletedNCT00566527Phase 3
46V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)CompletedNCT00109343Phase 3
47ProQuad® Intramuscular vs SubcutaneousCompletedNCT00402831Phase 3
48A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy ToddlersCompletedNCT00384397Phase 3
49Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy ToddlersCompletedNCT00626327Phase 3
50Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration RoutesCompletedNCT00351923Phase 3

Search NIH Clinical Center for Rubella


Cochrane evidence based reviews: Rubella

Genetic Tests for Rubella

About this section

Anatomical Context for Rubella

About this section

MalaCards organs/tissues related to Rubella:

33
Skin, Eye, Brain, Heart, Lymph node, Testes, T cells

FMA organs/tissues related to Rubella:

16
Skin

Animal Models for Rubella or affiliated genes

About this section

MGI Mouse Phenotypes related to Rubella:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053977.1C1QBP, CD40LG, DDX58, HLA-B, IL10, IL10RB
2MP:00053876.8C1QBP, CD40LG, DDX58, HLA-B, IL10, IL10RB

Publications for Rubella

About this section

Articles related to Rubella:

(show top 50)    (show all 1157)
idTitleAuthorsYear
1
Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9a88months of age: a phase III, randomised, non-inferiority trial. (26362659)
2015
2
Seroprevalence of measles, mumps and rubella among young adults, after 20A years of universal two-dose MMR vaccination in Israel. (25891446)
2015
3
Measles-Mumps-Rubella-Varicella Combination Vaccine (ProQuad(Ar)): A Guide to Its Use in Children in the EU. (25732634)
2015
4
Mumps antibody response in young adults after a third dose of measles-mumps-rubella vaccine. (25734162)
2014
5
Decline of varicella vaccination in German surveillance regions after recommendation of separate first-dose vaccination for varicella and measles-mumps-rubella. (24412300)
2014
6
Investigation of an outbreak of hypersensitivity-type reactions during the 2004 national measles-mumps-rubella vaccination campaign in Brazil. (23246259)
2013
7
Influence of Vaccination dose and clinico-demographical factors on antibody titers against measles, rubella, mumps, and varicella-zoster viruses among university students in Japan. (24270137)
2013
8
Magnetic resonance imaging findings in a case of congenital rubella encephalitis. (24489572)
2013
9
Rubella in Poland in 2011. (24040714)
2013
10
The importance of fundus eye testing in rubella-induced deafness. (23911114)
2013
11
Congenital rubella syndrome: a review of laboratory data from 2002 to 2011. (24050074)
2013
12
Enabling implementation of the Global Vaccine Action Plan: developing investment cases to achieve targets for measles and rubella prevention. (23598476)
2013
13
Congenital rubella syndrome and left pulmonary artery sling. (22298614)
2012
14
An outbreak of rubella in the Federation of Bosnia and Herzegovina between December 2009 and May 2010 indicates failure to vaccinate during wartime (1992-1995). (21524344)
2012
15
Letter to the editor: commitment needed for the prevention of congenital rubella syndrome in Europe. (22433598)
2012
16
Pityriasis lichenoides et varioliformis acuta: a rare association with the measles, mumps and rubella vaccine. (23157791)
2012
17
Rubella vaccines: WHO position paper--recommendations. (21930175)
2011
18
Development of microsatellite markers in Capsella rubella and Capsella bursa-pastoris (Brassicaceae). (21700797)
2011
19
Congenital rubella syndrome and autism spectrum disorder prevented by rubella vaccination--United States, 2001-2010. (21592401)
2011
20
Application of new assays for rapid confirmation and genotyping of isolates of rubella virus. (21108356)
2011
21
Unusual nucleotide content of Rubella virus genome as a consequence of biased RNA-editing: comparison with Alphaviruses. (21441098)
2011
22
Polymorphisms in the vitamin A receptor and innate immunity genes influence the antibody response to rubella vaccination. (20001730)
2010
23
Surveillance and control of rubella in the republic of Korea from 2001 to 2009: the necessity for enhanced surveillance to monitor congenital rubella syndrome. (24159436)
2010
24
Development of a novel TaqMan real-time PCR assay for detecting rubella virus RNA. (20580632)
2010
25
Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. (20587679)
2010
26
Could the United States experience rubella outbreaks as a result of vaccine refusal and disease importation? (21150305)
2010
27
Closer look at autism and the measles-mumps-rubella vaccine. (21071320)
2010
28
A measles and rubella (MR) catch-up vaccination campaign in an Egyptian University: vaccine uptake and knowledge and attitudes of students. (20797454)
2010
29
A relapse of systemic type juvenile idiopathic arthritis after a rubella vaccination in a patient during a long-term remission period. (19576941)
2009
30
Chlamydia trachomatis and rubella antibodies in women with full-term deliveries and women with abortion in Baghdad. (20218131)
2009
31
Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine. (19007835)
2009
32
Development of the rubella vaccine and vaccination strategy in Japan. (19366581)
2009
33
Humoral immune response to primary rubella virus infection. (16522781)
2006
34
Human leukocyte antigen class II alleles and rubella-specific humoral and cell-mediated immunity following measles-mumps-rubella-II vaccination. (15655774)
2005
35
Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy. (15717298)
2005
36
The risk of aseptic meningitis associated with the Leningrad-Zagreb mumps vaccine strain following mass vaccination with measles-mumps-rubella vaccine, Rio Grande do Sul, Brazil, 1997. (12435771)
2002
37
Previous exposure to measles, mumps, and rubella--but not vaccination during adolescence--correlates to the prevalence of pancreatic and thyroid autoantibodies. (10390298)
1999
38
Use of PCR for prenatal and postnatal diagnosis of congenital rubella. (8576339)
1995
39
Detection of rubella virus-specific immunoglobulin G (IgG), IgM, and IgA antibodies by immunoblot assays. (1572968)
1992
40
Rubella surveillance to december 1990: a joint report from the PHLS and National Congenital Rubella Surveillance Programme. (1669769)
1991
41
Development of a highly specific and sensitive rubella immunoglobulin M antibody capture enzyme immunoassay that uses enzyme-labeled antigen. (2185260)
1990
42
Congenital rubella syndrome in Malaysia. (3831727)
1985
43
Birth and death of congenital rubella syndrome. (6700106)
1984
44
The HLA system in congenital rubella patients with and without diabetes. (6959935)
1982
45
Congenital rubella syndrome: a continuing problem. (6799666)
1982
46
Congenital rubella, insulitis, and diabetes mellitus in an infant. (6112424)
1981
47
Keratoconus and acute hydrops in mentally retarded patients with congenital rubella syndrome. (7468739)
1981
48
Impaired cell-mediated immune response in patients with congenital rubella: correlation with gestational age at time of infection. (386238)
1979
49
The devastating effects of congenital rubella. (106205)
1979
50
Nuclear and cytoplasmic immunofluorescence in the cerebrospinal fluid cells from a neonate with congenital rubella. (347227)
1977

Variations for Rubella

About this section

Expression for genes affiliated with Rubella

About this section
Search GEO for disease gene expression data for Rubella.

Pathways for genes affiliated with Rubella

About this section

Pathways related to Rubella according to GeneCards Suite gene sharing:

(show all 18)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
9.5DDX58, IL10RB
29.1CD40LG, HLA-A, HLA-B, HLA-C
39.1CALR, HLA-A, HLA-B, HLA-C
4
TNF Signaling (sino)
Show member pathways
9.0CALR, HLA-A, HLA-B, HLA-C
5
Show member pathways
8.9HLA-A, HLA-B, HLA-C, IFNA21
68.7CD40LG, HLA-A, HLA-B, HLA-C, HLA-DPB1
78.7CALR, HLA-A, HLA-B, HLA-C, HLA-DPB1
88.7CALR, HLA-A, HLA-B, HLA-C, HLA-DPB1
9
Show member pathways
8.6CD40LG, HLA-DPB1, IL10, IL10RB
10
Show member pathways
8.6CALR, HLA-A, HLA-B, HLA-C, TPP2
118.5C1QBP, CD40LG, DDX58, IL10
128.3HLA-DPB1, IFNA21, IL10, IL10RB
13
Show member pathways
8.0HLA-A, HLA-B, HLA-C, IFNA21, IL10
14
Show member pathways
7.6C1QBP, DDX58, HLA-A, HLA-B, HLA-C, HLA-DPB1
15
Show member pathways
7.2DDX58, HLA-A, HLA-B, HLA-C, HLA-DPB1, IFNA21
167.1DDX58, HLA-A, HLA-B, HLA-C, HLA-DPB1, IL10
17
Show member pathways
6.8CALR, CD40LG, HLA-A, HLA-B, HLA-C, HLA-DPB1
18
Show member pathways
6.2CALR, CD40LG, DDX58, HLA-A, HLA-B, HLA-C

GO Terms for genes affiliated with Rubella

About this section

Cellular components related to Rubella according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1MHC class I protein complexGO:00426129.9HLA-A, HLA-B, HLA-C
2early endosome membraneGO:00319019.7HLA-A, HLA-B, HLA-C
3phagocytic vesicle membraneGO:00306709.5HLA-A, HLA-B, HLA-C
4ER to Golgi transport vesicle membraneGO:00125079.3HLA-A, HLA-B, HLA-C, HLA-DPB1
5integral component of lumenal side of endoplasmic reticulum membraneGO:00715569.1CALR, HLA-A, HLA-B, HLA-C, HLA-DPB1
6cell surfaceGO:00099868.2C1QBP, CALR, HLA-A, HLA-B, HLA-C, HLA-DPB1

Biological processes related to Rubella according to GeneCards Suite gene sharing:

(show all 25)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of dendritic cell chemotaxisGO:200051010.5C1QBP, CALR
2positive regulation of T cell mediated cytotoxicityGO:000191610.5HLA-A, HLA-B
3detection of bacteriumGO:001604510.5HLA-A, HLA-B
4positive regulation of substrate adhesion-dependent cell spreadingGO:190002610.5C1QBP, CALR
5protection from natural killer cell mediated cytotoxicityGO:004227010.5HLA-A, HLA-B
6protein trimerizationGO:007020610.5TRIM22, TRIM5
7antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independentGO:000248010.1HLA-A, HLA-B, HLA-C
8antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentGO:000248610.1HLA-A, HLA-B, HLA-C
9negative regulation of interleukin-12 productionGO:003269510.0C1QBP, IL10
10negative regulation of interferon-gamma productionGO:003268910.0C1QBP, IL10
11antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependentGO:00024799.5CALR, HLA-A, HLA-B, HLA-C
12type I interferon signaling pathwayGO:00603379.5HLA-A, HLA-B, HLA-C, IFNA21
13antigen processing and presentation of exogenous peptide antigen via MHC class IGO:00425909.5CALR, HLA-A, HLA-B, HLA-C
14antigen processing and presentationGO:00198829.5HLA-A, HLA-B, HLA-C, HLA-DPB1
15B cell differentiationGO:00301839.4CD40LG, IFNA21, IL10
16B cell proliferationGO:00421009.4CD40LG, IFNA21, IL10
17defense response to virusGO:00516079.2IFNA21, IL10RB, TRIM22, TRIM5
18antigen processing and presentation of peptide antigen via MHC class IGO:00024749.0CALR, HLA-A, HLA-B, HLA-C, TPP2
19positive regulation of sequence-specific DNA binding transcription factor activityGO:00510919.0DDX58, IL10, TRIM22, TRIM5
20interferon-gamma-mediated signaling pathwayGO:00603338.9HLA-A, HLA-B, HLA-C, HLA-DPB1, TRIM22, TRIM5
21regulation of immune responseGO:00507768.8CD40LG, HLA-A, HLA-B, HLA-C
22viral processGO:00160328.1C1QBP, DDX58, HLA-A, HLA-B, HLA-C, TRIM22
23innate immune responseGO:00450878.0C1QBP, DDX58, HLA-B, HLA-C, IFNA21, TRIM5
24cytokine-mediated signaling pathwayGO:00192217.5HLA-A, HLA-B, HLA-C, HLA-DPB1, IFNA21, IL10RB
25immune responseGO:00069557.3C1QBP, CD40LG, HLA-A, HLA-B, HLA-C, HLA-DPB1

Molecular functions related to Rubella according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1complement component C1q bindingGO:00018499.9C1QBP, CALR
2TAP bindingGO:00469779.6HLA-A, HLA-B, HLA-C
3peptide antigen bindingGO:00426059.0HLA-A, HLA-B, HLA-C, HLA-DPB1

Sources for Rubella

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet